Page 1

NANOBIOTIX EXPANDING LIFE Nanobiotix Provides Third Quarter Operational and Financial Update October 20 , 2021 • Published preclinical data in Red Journal supporting the hypothesis that NBTXR3 activated by radiotherapy in combination with anti - PD - 1 could effectively control primary and metastatic tumors , evoke abscopal effect , and reduce the possibility of developing distant lung metastases • Scheduled to present first survival data from priority head and neck cancer program at the 2021 Annual Meeting of the American Society for Radiation Oncology ( ASTRO ) • On - track to activate first clinical trial sites in pivotal phase III global registration study , NANORAY - 312 , in locally advanced head and neck squamous cell carcinoma ( LA - HNSCC ) in the coming weeks • Reported € 89.8 million in cash , cash equivalents , and short - term investments as of September 30 , 2021 Paris , France ; Cambridge , Massachusetts ( USA ) ; October 20 , 2021 – NANOBIOTIX ( Euronext : NANO- NASDAQ : NBTX - the " Company ' ) , a late - clinical stage biotechnology company pioneering physics - based approaches to expand treatment possibilities for patients with cancer , today announced operational progress and cash position ( unaudited ) for the third quarter of 2021 . Third Quarter Financial Updates Nanobiotix reported cash , cash equivalents , and short - term investments totaling € 89.8 million as of September 30 , 2021 , compared to € 119.2M as of December 31 , 2020 [ 1 ] . Third Quarter Operational Highlights and Upcoming Milestones • Published preclinical findings with The University of Texas MD Anderson Cancer Center ( MD Anderson ) in the International Journal of Radiation Oncology , Biology , Physics ( Red Journal ) supporting continued exploration of NBTXR3 as a potential therapeutic option to induce significant tumor cell death , prime immune response , and overcome resistance to anti - PD - 1 . • Study hypothesized that NBTXR3 in combination with radiotherapy and anti - PD - 1 could transform irradiated tumors into " self - vaccines " in anti - PD - 1 - sensitive and anti - PD - 1 - resistant mouse models • Data supported the hypothesis that the triple combination could effectively control primary and metastatic tumors , evoke abscopal effect , and reduce the possibility of developing distant lung metastases • Presenting two oral presentations and three poster presentations at the 2021 ASTRO Annual Meeting being held October 24-27 , 2021 , including : • First analysis of progression free survival ( PFS ) and overall survival ( OS ) from 41 evaluable patients from Study 102 Expansion , a phase I dose expansion study evaluating NBTXR3 as a single agent activated by radiotherapy in LA - HNSCC • Updated data including approximately 16 evaluable patients from Study 1100 , a phase I basket study evaluating NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in locoregional recurrent or recurrent metastatic HNSCC , lung metastasis from any primary tumor and / or liver metastasis from any primary tumor . Long - term safety data from the phase II / III Act.In. Sarc Trial of NBTXR3 in locally advanced soft tissue sarcoma • Preclinical data on NBTXR3 plus anti - PD - 1 in lung cancer model • Preparing to activate first clinical trial sites for NANORAY - 312 , a pivotal phase III global registration study evaluating NBTXR3 as a single - agent activated by radiotherapy for patients with LA - HNSCC • First site activations in Europe expected in the coming weeks with first patient randomized by early 2022 . • US site activation and enrollment planned for 2022 . [ 1 ] It being specified that the company did not generate any revenue during the third quarter of 2021 , this following the termination of the PharmaEngine partnership . About NANOBIOTIX Nanobiotix is a late - stage clinical biotechnology company pioneering disruptive , physics - based therapeutic approaches to revolutionize treatment outcomes for millions of patients ; supported by people committed to making a difference for humanity . The company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life . Incorporated in 2003 , Nanobiotix is headquartered in Paris , France . The company also has subsidiaries in Cambridge , Massachusetts ( United States ) , France , Spain , Germany and Switzerland . Nanobiotix has been listed on the regulated market of Euronext in Paris since 2012 and on the Nasdaq Global Select Market in New York